

Effectiveness of convalescent plasma therapy in COVID-19 patients

Ghazala Rubi

Lahore General Hospital, Pakistan

Background: COVID-19 is an infectious disease caused by a newly identified strain of coronavirus (SARS-CoV-2). This strain is responsible for respiratory infections in humans.

Objective: The objective of this study was to analyze the clinical efficacy and safety of Convalescent Plasma (CP) therapy in Corona Virus Disease 2019 (COVID-19) cases.

Design: This was an experimental trial of COVID-19 patients treated with Convalescent Plasma (CP) therapy; these patients were admitted in Lahore General Hospital, Lahore, Pakistan during April 24 to August 24, 2021.

Findings: Pearson correlation was applied to extract the efficacy of Convalescent Plasma therapy (CP). A p-value ≤ 0.05 was considered significant. 16 out of 20 patients (80%) were completely recovered from COVID-19.

Conclusions: Convalescent Plasma (CP) proved to be an effective and safe therapy for confirmed cases of COVID-19. However, two critically ill patients died.

Keywords: COVID-19, Convalescent Plasma (CP) therapy, Symptoms, Critically ill.

Biography

Ghazala Rubi is the Director of Research Laboratory. She completed her Post Graduation in Medical Institute & Lahore General Hospital, Lahore, Pakistan.

Received: January 05, 2023; **Accepted:** January 09, 2023; **Published:** February 22, 2023
